
https://www.science.org/content/blog-post/medical-periodic-table
# The Medical Periodic Table (May 2013)

## 1. SUMMARY

This article reviews a 2013 Chemical Communications paper that presented a "medical periodic table" categorizing elements by their therapeutic applications. The table used color coding to distinguish essential elements (white), drug-containing elements (blue), diagnostic elements (orange), and medically useful radioisotopes (green). The author discusses the classification challenges, noting that some elements are excluded due to radioactivity, toxicity, or simply lacking demonstrated medical utility.

The article surveys existing metal-containing drugs, particularly platinum anticancer agents, with ruthenium, osmium, and iridium compounds also in clinical development. Titanium (as titanocene dichloride) had disappointing clinical results, while arsenic compounds have historical precedent and recent renewed interest. The author notes that most medicinal chemists regard these as "weirdo metals" and expresses uncertainty about their pharmacokinetic and toxicological properties. The piece concludes that metal-containing compounds face significant barriers to adoption, limited largely to oncology and infectious diseases where conventional approaches fail.

## 2. HISTORY

Since 2013, progress in metallodrug development has been mixed but has shown specific notable advances rather than broad-based adoption:

**Cancer Therapeutics Evolution**: Platinum-based chemotherapy remains foundational in oncology (cisplatin, carboplatin, oxaliplatin), with no fundamentally new approved platinum drugs since 2013. However, there have been significant improvements in delivery mechanisms and combination therapies that enhance efficacy while reducing toxicity. PARP inhibitors, which work synergistically with platinum drugs, have become important combination partners, particularly in BRCA-mutant cancers.

**Ruthenium Development**: Several ruthenium compounds have advanced through clinical trials, though with challenges. TLD1433 (a ruthenium-based photosensitizer) entered clinical trials for non-muscle invasive bladder cancer treatment, validating ruthenium's potential in photodynamic therapy applications. However, broader ruthenium-based chemotherapy has not achieved widespread clinical adoption.

**Radiopharmaceuticals Expansion**: The most significant development in metal-based medicine since 2013 has been in therapeutic radiopharmaceuticals. Lutetium-177 PSMA-617 (Pluvicto) received FDA approval in 2022 for metastatic castration-resistant prostate cancer, representing a major breakthrough. The field of theranostics has expanded substantially, with gallium-68 and other metal-based diagnostic agents pairing with therapeutic counterparts.

**Antibiotic Resistance**: Metal-based antibiotics have seen increased research focus due to antimicrobial resistance, but no major new metal-containing antibiotics have reached clinical practice. Some research has explored gallium as an iron mimetic and silver-containing compounds, but these remain niche applications.

**Drug Delivery Innovation**: Advances in nanoparticle drug delivery have utilized various metals for targeted delivery, though these are primarily delivery mechanisms rather than active pharmaceutical ingredient innovations.

## 3. PREDICTIONS

• **Prediction**: Metal-containing compounds would primarily succeed in "nothing-else-works areas" like oncology and gram-negative antibiotics.
  
  **Outcome**: Partially accurate. Platinum drugs remain entrenched in oncology, and radiopharmaceuticals have achieved significant success in late-stage cancers (particularly prostate cancer with Pluvicto). However, metal-based antibiotics have not achieved comparable success despite ongoing research into resistance mechanisms.

• **Prediction**: Exotic metal compounds would face skepticism and limited adoption due to lack of PK/tox understanding and limited compound library inclusion.
  
  **Outcome**: Accurate. Even by 2024, novel metal-containing drugs face higher regulatory and development barriers. Most pharmaceutical companies maintain few metal-containing compounds in screening libraries, creating a catch-22 for development.

• **Prediction**: Protein-protein interaction targets would remain unexplored territory for metal compounds.
  
  **Outcome**: Mostly accurate. While there has been increased research into allosteric modulation and protein degradation (PROTACs), metal-based approaches to these targets remain rare and haven't produced approved drugs.

• **Prediction**: Arsenic compounds would see continued development given their historical use and mechanism.
  
  **Outcome**: Accurate. Arsenic trioxide remains important for acute promyelocytic leukemia treatment, but expanded use has been limited by toxicity concerns. The thioredoxin pathway mechanism mentioned has been validated but hasn't translated into broad therapeutic applications.

• **Implied prediction**: The "medical periodic table" would expand as more elements found therapeutic applications.
  
  **Outcome**: Limited expansion. While radiopharmaceutical applications have grown (Lu-177, Ga-68, others), the fundamental challenge remains that the elements with most therapeutic potential were already identified by 2013. Newer elements finding medical use have been primarily in specialized imaging and radiotherapy rather than broad therapeutic applications.

## 4. INTEREST

Rating: **6/10**

The article merits moderate interest as a snapshot of metal-based drug development at a particular moment, accurately noting barriers that persist over a decade later while having mixed record on specific progress predictions. The accompanying "medical periodic table" concept provides useful pedagogical framework, though the broader therapeutic impact of metallodrugs remains constrained.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20130506-medical-periodic-table.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_